c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model

Lung Cancer

Volumn 60, Issue 3, 2008, Pages 347-354

  Sekhon, Harmanjatinder S ^c   London, Carla A ^a   Sekhon, Mypinder ^c   Iversen, Patrick L ^a   Devi, Gayathri R ^b  

^a AVI BIOPHARMA INC   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

c MYC; Lung cancer; Metastasis; MMP 9; Phosphorodiamidate morpholino oligomer

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; AVI 4126; GELATINASE B; MESSENGER RNA; MYC PROTEIN; PHOSPHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; EXTRAVASATION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG METASTASIS; MALE; MITOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENES, MYC; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MICE, NUDE; MORPHOLINES; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 44249084916     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.10.028     Document Type: Article

References (34)

1. Akoglu S., Ucan E.S., Celik G., Sener G., Sevinc C., Kilinc O., et al. Endobronchial metastases from extrathoracic malignancies. Clin Exp Metastasis 22 (2005) 587-591
2. Morgan-Parkes J.H. Metastases: mechanisms, pathways, and cascades. AJR Am J Roentgenol 164 (1995) 1075-1082
3. Ponzielli R., Katz S., Barsyte-Lovejoy D., and Penn L.Z. Cancer therapeutics: targeting the dark side of Myc. Eur J Cancer 41 (2005) 2485-2501
4. Nilsson J.A., and Cleveland J.L. Myc pathways provoking cell suicide and cancer. Oncogene 22 (2003) 9007-9021
5. Adhikary S., and Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6 (2005) 635-645
6. Felsher D.W., and Bradon N. Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect 16 (2003) 370-374
7. Arora V., Devi G.R., and Iversen P.L. Neutrally charged phosphorodiamidate Morpholino antisense oligomers: uptake, efficacy, and pharmacokinetics. Curr Pharm Biotech 5 (2004) 431-439
8. Hudziak R.M., Summerton J., Weller D.D., and Iversen P.L. Antiproliferative effects of steric blocking phosphorodiamidate morpholino antisense agents directed against c-myc. Antisense Nucleic Acid Drug Dev 10 (2000) 163-176
9. Giles R.V., Spiller D.G., Clark R.E., and Tidd D.M. Antisense morpholino oligonucleotide analog induces missplicing of c-myc mRNA. Antisense Nucleic Acid Drug Dev 9 (1999) 213-220
10. Devi G.R. Prostate cancer: status of current treatments and emerging antisense-based therapies. Curr Opin Mol Therap 4 (2002) 138-148
11. Summerton J., and Weller D. Morpholino antisense oligomers: design, preparation and properties. Antisense Nucleic Acid Drug Dev 7 (1997) 187-195
12. Summerton J., Stein D., Huang S.B., MatthewsP, Weller D., and Partridge M. Morpholino and phosphorothioate oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev 7 (1997) 63-70
13. Ghosh C., Stein D., Weller D., and Iversen P.L. Evaluation of antisense mechanisms of action. Methods Enzymol 313 (2000) 135
14. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type. Biochim Biophys Acta 1489 (1999) 141-158
15. Wu R.P., Youngblood D.S., Hassinger J.N., Lovejoy C.E., Nelson M.H., Iversen P.L., et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 35 (2007) 5182-5191
16. Arora V., Knapp D.C., Smith B.L., et al. c-Myc antisense rat liver regeneration and indicates role for c-myc in regulating cytochrome P-450 3A activity. J Pharmacol Expt Ther 292 (2000) 921-928
17. Knapp D.C., Mata J.E., Reddy M.T., Devi G.R., and Iversen P.L. Resistance to chemotherapeutic drugs overcome by c-Myc inhibition in Lewis lung carcinoma murine model. Anti-Cancer Drugs 14 (2003) 39-47
18. Devi G.R., Oldenkamp J.R., London C.A., and Iversen P.L. Inhibition of human chorionic gonadotropin beta subunit modulates the mitogenic effect of c-myc in human prostate cancer cells. Prostate 53 (2002) 200-210
19. Arora V., Knapp D.C., Reddy M.T., Weller D.D., and Iversen P.L. Bioavailability and efficacy of antisense morpholino oligomers targeted to c-Myc and cytochrome P-450 3A2 following oral administration in rats. J Pharm Sci 91 (2002) 1009-1017
20. Egeblad M., and Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 (2002) 161-174
21. Baruch R.R., Melinscak H., Lo J., Liu Y., Yeung O., and Hurta R.A. Altered matrix metalloproteinase expression associated with oncogene-mediated cellular transformation and metastasis formation. Cell Biol Int 25 (2001) 411-420
22. Magid R., Murphy T.J., and Galis Z.S. Expression of matrix metalloproteinase-9 in endothelial cells is differentially regulated by shear stress. Role of c-Myc. J Biol Chem 278 (2003) 32994-32999
23. London C.A., Sekhon H.S., Arora V., Stein D.A., Iversen P.L., and Devi G.R. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity. Cancer Gene Ther 10 (2003) 823-832
24. Kipshidze N., Keane E., Stein D., et al. Local delivery of c-myc neutrally charged antisense oligonucleotides with transport catheter inhibits myointimal hyperplasia and positively affects vascular remodeling in the rabbit balloon injury model. Catheter Cardiovasc Interv 54 (2001) 247-256
25. Kipshidze N.N., Iversen P., Kim H.S., et al. Systemic targeted delivery of antisense with perflourobutane gas microbubble carrier reduced neointimal formation in the porcine coronary restenosis model. Cardiovasc Radiat Med 4 (2003) 152-159
26. Iversen P.L., Kipshidze N., Moses J.W., and Leon M.B. Local application of antisense for prevention of restenosis. Methods Mol Med 106 (2004) 37-50
27. Ricker J.L., Mata J.E., Iversen P.L., and Gattone V.H. c-myc antisense oligonucleotide treatment ameliorates murine ARPKD. Kidney Int 61 Suppl 1 (2002) 125-131
28. Iversen P.L., Arora V., Acker A.J., Mason D.H., and Devi G.R. Efficacy of antisense morpholino oligomer targeted to c-MYC in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res 9 (2003) 2510-2519
29. Levin A.A. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta 1489 (1999) 69-84
30. Crooke R.M. In vitro and in vivo toxicology of first generation analogs. In: Crooke S.T., and Lebleu B. (Eds). Antisense research and applications (1993), CRC Press, Inc. 471-491
31. Storey A., Oates D., Banks L., Crawford L., and Crook T. Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res 19 (1991) 4109-4114
32. Devi G.R., Beer T.M., Corless C.L., Arora V., Weller D.L., and Iversen P.L. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 11 (2005) 3930-3938
33. Kaltz-Wittmer C., Klenk U., Glaessgen A., et al. FISH analysis of gene aberrations in advanced prostatic carcinomas before and after androgen deprivation therapy. Lab Invest 80 (2000) 1455-1464
34. Carroll J.S., Swarbrick A., Musgrove E.A., and Sutherland R.L. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens. Cancer Res 62 (2002) 3126-3131